Successful desensitization of two patients with ALK-positive lung cancer and hypersensitivity to crizotinib

21Citations
Citations of this article
23Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The tyrosine kinase inhibitor crizotinib is an effective therapy for patients with cancers harboring rearrangements of the anaplastic lymphoma kinase (ALK) gene. Here, we describe two patients with advanced ALK-positive lung cancer who developed hypersensitivity to crizotinib, requiring temporary discontinuation of the drug. Both patients were treated with a rapid oral desensitization protocol allowing them to resume crizotinib without further signs or symptoms of hypersensitivity.

Cite

CITATION STYLE

APA

Awad, M. M., Lax, T. P., Slawski, B. R., & Shaw, A. T. (2014). Successful desensitization of two patients with ALK-positive lung cancer and hypersensitivity to crizotinib. Journal of Thoracic Oncology, 9(11), 1726–1728. https://doi.org/10.1097/JTO.0000000000000350

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free